Murph
:)
- Messages
- 1,799
This speech goes over the history of Rituximab in ME/CFS but it includes a few choice tidbits too.
1. They have an upcoming paper on endothelial function in the RituxME patients. I remember they once showed a slide showing changes in "flow-mediated dilation" and I have always subscribed to a blood flow theory so I'm excited by this. Any research on blood flow overlaps with the OMF red-blood cell work too.
2. They are running pilot study with exercise monitoring. (22 min) to try to find better end points that they could use for a new trial, rather than just self-reported measures.
3. In trying to explain why Rituximab does not work for the average patient, he wonders if the disease is perpetuated by autoantibodies from mature plasma cells, that are not affected by Rituximab, like Lupus. if they do another Ritux trial they will use a different selection criteria than Canadian criteria, perhaps a laboratory test.
4. The Cyclophosphamide trial data will be published in 2019. If you want my interepretation, when he puts an exclamation mark after the words Interesting data, like this:
Interesting data!
it means the preliminary results show it is effective. The problem being that it was an open-label trial like the early Rituximab trials. His slide says:
Open-label design and no placebo group = no firm conclusions.
So, hope persists!
Last edited: